- Home
- VCNX vs ISPC Comparison
VCNX vs ISPC Comparison
Compare VCNX & ISPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCNX
- ISPC
- Stock Information
- Founded
- VCNX 2001
- ISPC 2009
- Country
- VCNX United States
- ISPC United States
- Employees
- VCNX N/A
- ISPC N/A
- Industry
- VCNX Biotechnology: Pharmaceutical Preparations
- ISPC Precision Instruments
- Sector
- VCNX Health Care
- ISPC Health Care
- Exchange
- VCNX Nasdaq
- ISPC Nasdaq
- Market Cap
- VCNX 4.5M
- ISPC 4.7M
- IPO Year
- VCNX N/A
- ISPC 2021
- Fundamental
- Price
- VCNX $3.22
- ISPC $4.20
- Analyst Decision
- VCNX
- ISPC
- Analyst Count
- VCNX 0
- ISPC 0
- Target Price
- VCNX N/A
- ISPC N/A
- AVG Volume (30 Days)
- VCNX 167.3K
- ISPC 954.4K
- Earning Date
- VCNX 11-29-2024
- ISPC 11-07-2024
- Dividend Yield
- VCNX N/A
- ISPC N/A
- EPS Growth
- VCNX N/A
- ISPC N/A
- EPS
- VCNX N/A
- ISPC N/A
- Revenue
- VCNX $388,000.00
- ISPC $10,390,702.00
- Revenue This Year
- VCNX N/A
- ISPC $13.82
- Revenue Next Year
- VCNX N/A
- ISPC $11.76
- P/E Ratio
- VCNX N/A
- ISPC N/A
- Revenue Growth
- VCNX N/A
- ISPC 0.74
- 52 Week Low
- VCNX $1.39
- ISPC $3.41
- 52 Week High
- VCNX $13.02
- ISPC $12.60
- Technical
- Relative Strength Index (RSI)
- VCNX 48.87
- ISPC 44.46
- Support Level
- VCNX $2.87
- ISPC $4.19
- Resistance Level
- VCNX $3.43
- ISPC $4.83
- Average True Range (ATR)
- VCNX 0.53
- ISPC 0.57
- MACD
- VCNX 0.05
- ISPC -0.02
- Stochastic Oscillator
- VCNX 23.22
- ISPC 38.16
About VCNX Vaccinex Inc.
Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.